Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1619-1560
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial ; volume:31 ; number:6 ; day:17 ; month:10 ; year:2021 ; pages:699-711 ; date:12.2021
Clinical autonomic research ; 31, Heft 6 (17.10.2021), 699-711, 12.2021
- Creator
-
Kaufmann, Horacio
Vickery, Ross
Wang, Whedy
Kanodia, Jitendra
Shibao, Cyndya A.
Norcliffe-Kaufmann, Lucy
Haumann, Brett
Biaggioni, Italo
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10286-021-00827-0
- URN
-
urn:nbn:de:101:1-2022020418591217145229
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kaufmann, Horacio
- Vickery, Ross
- Wang, Whedy
- Kanodia, Jitendra
- Shibao, Cyndya A.
- Norcliffe-Kaufmann, Lucy
- Haumann, Brett
- Biaggioni, Italo
- SpringerLink (Online service)
Other Objects (12)
Neurogenic orthostatic hypotension: grand rounds
Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?
Neurogenic orthostatic hypotension: the very basics
Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer
Norepinephrine reuptake blockade to treat neurogenic orthostatic hypotension
Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension
Update on neurogenic orthostatic hypotension : pathophysiology, prevalence and treatment
Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension
Pharmacokinetics and pharmacodynamics of ampreloxetine, a novel, selective norepinephrine reuptake inhibitor, in symptomatic neurogenic orthostatic hypotension
Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension
Orthostatic hypotension
Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms
Neurogenic orthostatic hypotension: grand rounds
Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?
Neurogenic orthostatic hypotension: the very basics
Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer
Norepinephrine reuptake blockade to treat neurogenic orthostatic hypotension
Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension
Update on neurogenic orthostatic hypotension : pathophysiology, prevalence and treatment
Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension
Pharmacokinetics and pharmacodynamics of ampreloxetine, a novel, selective norepinephrine reuptake inhibitor, in symptomatic neurogenic orthostatic hypotension
Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension
Orthostatic hypotension
Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms
Neurogenic orthostatic hypotension: grand rounds
Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?
Neurogenic orthostatic hypotension: the very basics
Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer
Norepinephrine reuptake blockade to treat neurogenic orthostatic hypotension
Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension
Update on neurogenic orthostatic hypotension : pathophysiology, prevalence and treatment
Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension
Pharmacokinetics and pharmacodynamics of ampreloxetine, a novel, selective norepinephrine reuptake inhibitor, in symptomatic neurogenic orthostatic hypotension
Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension
Orthostatic hypotension